The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...
Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data, highlighting its ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Monday that the U.S. Food and Drug Administration or FDA has approved an updated label for Qelbree or ...
Qelbree has helped me manage my ADHD symptoms, and I have Supernus to thank for that.” October is ADHD Awareness Month, an important time to bring attention to the often complicated diagnosis ...
MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission ...
The new information in Section 12.2 of the label details Qelbree's partial agonist activity at the serotonin 5-HT2C receptor and its inhibition of the norepinephrine transporter. This multimodal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback